Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2026 09:00 ET | Source: Environmental & Public Health International

Cleveland CLASH Integrates Lead Service Line Planning Tool into Public Health Resources

Cleveland CLASH integrates EPHI’s LSLRCC into public resources, expanding access to cost and planning tools for lead service line replacement.
April 02, 2026 08:00 ET | Source: Neurologic Wellness Institute

Brain Injury Awareness Month: Why “Wait and See” Isn’t Always Enough

CHICAGO, IL, April 02, 2026 (GLOBE NEWSWIRE) -- March is Brain Injury Awareness Month, and clinicians at The Neurologic Wellness Institute want the public to understand something that often gets...
April 01, 2026 16:30 ET | Source: XWELL, Inc.

XWELL Reports Fiscal 2025 Results

NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), a leading provider of wellness solutions for people on the go, today announced financial results...
April 01, 2026 07:00 ET | Source: MADD Canada

En cette longue fin de semaine de Pâques, choisissez la prudence : conduisez sobre

OAKVILLE, Ontario, 01 avr. 2026 (GLOBE NEWSWIRE) -- Alors que familles et amis se réunissent pour célébrer Pâques, qui marque également la première longue fin de semaine du printemps, MADD Canada...
April 01, 2026 07:00 ET | Source: MADD Canada

This Easter Long Weekend, Choose Safety, Drive Sober

OAKVILLE, Ontario, April 01, 2026 (GLOBE NEWSWIRE) -- As families and friends gather to celebrate Easter, which also marks the first long weekend of spring, MADD Canada is urging everyone to make...
April 01, 2026 02:40 ET | Source: AskBio Inc. (AskBio)

AskBio Announces Completion of Enrollment in Phase 2 Clinical Trial of AB-1002 Investigational Gene Therapy for Heart Failure

Durham, N.C., April 01, 2026 (GLOBE NEWSWIRE) -- Final participant randomized in the GenePHIT Phase 2 clinical trial assessing safety and efficacy of AB-1002 for adults with non-ischemic...
March 31, 2026 08:30 ET | Source: Research and Markets

$4.26 Billion Brain Tumor Drugs Market 2026: Trends and Growth Outlook to 2030 & 2035

Dublin, March 31, 2026 (GLOBE NEWSWIRE) -- The "Brain Tumor Drugs Market Report 2026" has been added to ResearchAndMarkets.com's offering. The brain tumor drugs market has witnessed robust...
March 31, 2026 08:30 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

– A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission – IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus...
March 31, 2026 07:00 ET | Source: Biomea Fusion, Inc.

Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled with a GLP-1 receptor agonist-based therapyTopline...
March 30, 2026 13:33 ET | Source: Feature Impact

Heart Risks Go Beyond the Heart: Don’t Forget to Check Blood Sugar and Kidney Health

Learning about cardiovascular-kidney-metabolic syndrome can be a helpful step in understanding your overall health picture.